Dare Bioscience Inc Dossier
Qualitative Analysis
Business overview
Daré Bioscience, Inc. (NASDAQ: DARE) is a purpose-driven, clinical-stage biopharmaceutical company solely focused on identifying, developing, and bringing to market innovative products for women's health. The company's diverse portfolio spans key therapeutic areas including contraception, vaginal health, sexual health, and menopause. Its lead product candidates include Ovaprene®, a novel hormone-free monthly contraceptive licensed to Bayer, and DARE-HPV, an investigational treatment for persistent high-risk HPV infection. Daré is transitioning into a commercial-stage entity by launching products through compounding and consumer health channels, such as DARE to PLAY™ (topical sildenafil cream) and Flora Sync LF5™ vaginal probiotic capsules.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pursuing traditional FDA approval pathways (505(b)(2) NDA) while simultaneously securing earlier market access and near-term revenue via Section 503B compounding and consumer health channels.
Expected impact: Enables capital-efficient market building, early brand awareness, and diversified revenue streams prior to formal FDA approvals.
Partnering with digital health platforms and telehealth providers, with Medvantx Pharmacy serving as the national dispensing and fulfillment hub for DARE to PLAY.
Expected impact: Maximizes patient access and commercial reach with minimal traditional sales force infrastructure, optimizing capital efficiency.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Serves as the exclusive dispensing pharmacy and digital fulfillment hub for the national launch of DARE to PLAY sildenafil cream.
Terms: Fulfillment and service-based fees integrated into commercial readiness expenses.
Provides up to $10 million in milestone-based contract funding to support the clinical development of DARE-HPV.
Terms: Up to $10 million in milestone-based contract funding over two years.